Translator Disclaimer
1 March 2016 MANAGEMENT OF OSTEOARTHRITIS IN A GIANT PANDA (AILUROPODA MELANOLEUCA) WITH MULTIMODAL THERAPY INCLUDING AMANTADINE SULPHATE
Author Affiliations +
Abstract

In 2002 a 23-yr-old female giant panda (Ailuropoda melanoleuca) presented with left hind limb lameness presumably due to osteoarthritis. For the next five years, arthritic episodes were managed with the nonsteroidal anti-inflammatory drug (NSAID) carprofen at 2 mg/kg p.o. s.i.d., then reduced to 1 mg/kg p.o. s.i.d. and withdrawn. Radiographs revealed osteoarthritis in various joints and lumbar spondylosis. In 2007 glucosamine and chondroitin at 1.65 g p.o. b.i.d. and a polyunsaturated fatty acid at 1 capsule p.o. s.i.d. By 2008, arthritic episodes were becoming more difficult to successfully manage and higher doses and longer durations of treatment with carprofen were needed (2 mg/kg p.o. b.i.d.) and by August 2009 episodic treatment was no longer successful so the carprofen was continued indefinitely at 1 mg/kg p.o. s.i.d. In November 2009 carprofen was increased to 2 mg/kg p.o. b.i.d. An NMDA antagonist amantadine sulphate was trialed and after 10 days at 200 mg p.o. s.i.d. the clinical signs resolved. Since then it has been maintained on carprofen at 1 mg/kg p.o. b.i.d., amantadine sulphate 200 mg p.o. s.i.d. and the neutraceuticals as above with no further relapses of arthritic pain.

Copyright 2016 by American Association of Zoo Veterinarians
Nimal Fernando, Elke Wu, Cissy Kou, Paolo Martelli, Lee Foo Khong, and Kathy Larson "MANAGEMENT OF OSTEOARTHRITIS IN A GIANT PANDA (AILUROPODA MELANOLEUCA) WITH MULTIMODAL THERAPY INCLUDING AMANTADINE SULPHATE," Journal of Zoo and Wildlife Medicine 47(1), 325-328, (1 March 2016). https://doi.org/10.1638/2013-0134.1
Received: 4 September 2014; Published: 1 March 2016
JOURNAL ARTICLE
4 PAGES


SHARE
ARTICLE IMPACT
RIGHTS & PERMISSIONS
Get copyright permission
Back to Top